After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.
Teva Pharmaceutical Industries, whose manufacturing operation is being signifcantly pared down, is recalling one lot of its generic Parkinson's combo drug carbidopa/levodopa because it may have too much active pharmaceutical ingredient.
Teva's long-acting version of multiple sclerosis treatment Copaxone has surpassed most analysts' expectations. But as competition to the original looms, will Teva consider discontinuing off-patent Copaxone to push patients toward the protected version in a quest to maintain market share? The short answer: Yes, but not just yet.
Teva Pharmaceutical Industries, which in April had to recall a children's growth hormone, has now halted production of a parenteral nutrition product as the authorities try to determine why 9 children in Israel developed blood infections after taking it.
Rebel investor Benny Landa has already won some of his demands from Teva's leadership, including a smaller board with more pharma experience. Now, he's angling for more boardroom changes--and if Teva won't make them, he says, he will.
Controversial Teva chairman Phillip Frost may not be leaving until the end of this year, but the company already has its next chairman lined up. That's according to one of the company's activist investors. And he doesn't much like its pick.
European regulators are getting the hang of levying pay-for-delay penalties, rolling up 6 companies in its latest action and fining them more than half a billion dollars in the process.
Teva just won't give up on delaying generic Copaxone. Its latest tactic: filing a citizen petition with the FDA to once again push for full-scale, placebo-controlled clinical trials for all copies of its multiple sclerosis med.
Israel-based Teva Pharmaceutical Industries, in the midst of restructuring its manufacturing network, has faced a number of recalls of late. Now a New Jersey company is recalling nearly 130,000 cartons of Teva's human growth hormone for children because there is a chance that oil leaked into it.
In January, Teva chairman Dr. Phillip Frost promised some changes to the company's board in response to investor pressure. But it wasn't until Wednesday that he announced his own exit would be among them.